Review
Biochemistry & Molecular Biology
Helena Idborg, Vilija Oke
Summary: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by activation and dysregulation of the immune system. Disturbances in immune pathways and genetic susceptibility are key factors in the development of SLE. Dysregulation of cytokines, particularly interferons, has been extensively studied as potential biomarkers and treatment targets in SLE.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Medicine, General & Internal
Ami Schattner
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse and atypical presentations. Early diagnosis is crucial for better outcomes, but the nonspecific symptoms and unusual organ involvement often lead to diagnostic delays.
AMERICAN JOURNAL OF MEDICINE
(2022)
Article
Medicine, Research & Experimental
Nan Xiang, Xuan Fang, Xiao-Ge Sun, Ying-Bo Zhou, Yan Ma, Chen Zhu, Xiang-Pei Li, Guo-sheng Wang, Jin-hui Tao, Xiao-Mei Li
Summary: SLE patients showed increased percentages of CD4(+)PU.1(+)T cells and PU.1 mRNA expression in CD4(+)T cells, with a positive correlation with plasma IL-1β expression. However, there were no significant correlations between PU.1 mRNA expression and major clinical/laboratory parameters of SLE patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Immunology
Mi-Ae Lyu, Ximing Tang, Joseph D. Khoury, Maria Gabriela Raso, Meixian Huang, Ke Zeng, Mitsutaka Nishimoto, Hongbing Ma, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar
Summary: This study found that treatment with UCB-Tregs can reduce the inflammatory burden in SLE, decrease autoantibody production, and improve kidney function. UCB-Tregs have the potential to be a therapeutic option for lupus nephritis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Izumi Kurata, Natsuko Mikami, Ayako Ohyama, Atsumu Osada, Yuya Kondo, Hiroto Tsuboi, Takayuki Sumida, Isao Matsumoto
Summary: The study found that SLE-TFR cells have functional defects in suppressing TFH cells, leading to decreased ability to inhibit them, and their PD-1 expression is correlated with disease activity and antibody levels. However, low-dose IL-2 therapy may be helpful in restoring this inhibitory function.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2021)
Review
Rheumatology
Fan Yang, Jin Lin, Weiqian Chen
Summary: Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by multiple autoantibodies and immune-mediated tissue damage. While a new drug, belimumab, shows promise in improving SLE conditions, the discovery of novel therapeutic targets is urgently needed. Protein post-translational modifications (PTMs) may play key roles in regulating T-cell function and signaling pathways in SLE pathogenesis, presenting potential new targets for therapy.
Article
Immunology
Ram P. Singh, David S. Bischoff
Summary: Gender and sex hormones can influence susceptibility to SLE by affecting regulatory T cells and FoxP3 expression, with females being more susceptible than males. Female SLE patients have higher estradiol levels and lower testosterone levels, which may lead to reduced T-regulatory cells and decreased FoxP3 expression, contributing to the increased susceptibility to SLE and other autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Konstantinos Parperis, Nikolaos Velidakis, Elina Khattab, Evangelia Gkougkoudi, Nikolaos P. E. Kadoglou
Summary: Pulmonary hypertension is commonly seen in patients with systemic lupus erythematosus, presenting with non-specific symptoms and negatively affecting survival. It can result from immune system dysregulation, as well as various other conditions. Early diagnosis and identification of underlying pathogenetic mechanisms are crucial for introducing targeted therapy and preventing irreversible pulmonary vascular damage. The management of pulmonary hypertension in SLE patients is similar to that of idiopathic PAH, but specific diagnostic tools for early diagnosis seem to be unavailable yet.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Ram P. Singh, Bevra H. Hahn, David S. Bischoff
Summary: Recent evidence suggests a connection between inflammatory pathways and the female sex hormone 17 beta-estradiol, leading to immune dysregulation in SLE patients. Treatment with 17 beta-estradiol increases expression of pro-inflammatory cytokines and chemokines, as well as interferon-stimulated genes in both healthy individuals and SLE patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Genetics & Heredity
Wen Ma, Yu-Lung Lau, Wanling Yang, Yong-Fei Wang
Summary: The study aimed to improve SLE prediction accuracy using machine-learning algorithms, and the results showed that the random forest (RF) model performed well in SLE classification.
FRONTIERS IN GENETICS
(2022)
Review
Biochemistry & Molecular Biology
Patricia Richter, Anca Cardoneanu, Alexandra Maria Burlui, Luana Andreea Macovei, Ioana Bratoiu, Oana Nicoleta Buliga-Finis, Elena Rezus
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the imbalance of pro-inflammatory and anti-inflammatory cytokines. The dysregulation of JAK-STAT pathways plays a crucial role in SLE pathogenesis. JAK inhibitors have the potential to become the next stage in SLE therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Amirhossein Azari Jafari, Mojtaba Keikha, Seyyedmohammadsadeq Mirmoeeni, Mohammad Taghi Rahimi, Reza Jafari
Summary: The study systematically reviewed the use of live parasites or parasitic products in treating mouse models of SLE, demonstrating potential immunomodulating effects on improving immunologic cells and pathological changes.
AUTOIMMUNITY REVIEWS
(2021)
Review
Biochemistry & Molecular Biology
Patricia Richter, Anca Cardoneanu, Ciprian Rezus, Alexandra Maria Burlui, Elena Rezus
Summary: Cardiovascular diseases are a leading cause of high mortality in SLE patients, and traditional risk factors are insufficient in predicting their risk. Inflammation has been found to play a crucial role in the development of atherosclerosis in SLE, highlighting the need for new biomarkers to assess subclinical CVD risk.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Tomohiro Koga, Kunihiro Ichinose, George C. Tsokos
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. Immune abnormalities contribute to the expression of the disease, with elements of the immune system instigating cellular damage. Correcting immune aberrations and preventing organ damage are both important.
CLINICAL IMMUNOLOGY
(2022)
Article
Rheumatology
Ming Zhao, Delong Feng, Longyuan Hu, Lin Liu, Jiali Wu, Zhi Hu, Haojun Long, Qiqi Kuang, Lianlian Ouyang, Qianjin Lu
Summary: This study aimed to elucidate the three-dimensional genome structure and its impact on gene expression networks in systemic lupus erythematosus (SLE). Through analysis of CD4(+) T cells from SLE patients and healthy controls, it was found that SLE patients had distinct genome structures compared to healthy controls, which were closely associated with disease activity. Additionally, loops within chromosomes associated with disease activity and differentially expressed genes were identified, along with key histone modifications close to these loops. The study provides a foundation for further investigation into the relationship between chromosome structure and gene expression control in SLE.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
